{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/driving-faster-respiratory-clinical-trial-biotech#webpage",
"url": "https://www.fortrea.com/insights/driving-faster-respiratory-clinical-trial-biotech",
"name": "Meeting aggressive data delivery timelines in one of the first‑ever CAR‑T studies with pediatric and adolescent patients",
"description": "This Fortrea case study explores how a proactive clinical data management and site support strategy helped meet aggressive data delivery timelines in one of the first-ever CAR-T studies involving pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) and relapsed/refractory B-cell non-Hodgkin lymphoma. As part of a broader CAR-T cell therapy development program, the study required management of significant operational complexity while maintaining high standards of data integrity and data quality. Fortrea implemented a focused approach centered on prioritizing site support, overseeing critical data review activities, accelerating data analysis readiness, and proactively addressing study challenges throughout execution. By supporting data integrity efforts and streamlining operational processes, Fortrea delivered primary analysis deliverables ahead of schedule, enabling timely sponsor decision-making and successful progression of the pediatric CAR-T clinical development program"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Meeting aggressive data delivery timelines in one of the first‑ever CAR‑T studies with pediatric and adolescent patients",
"item": "https://www.fortrea.com/insights/driving-faster-respiratory-clinical-trial-biotech"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/driving-faster-respiratory-clinical-trial-biotech#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/driving-faster-respiratory-clinical-trial-biotech#webpage"
},
"headline": "Pediatric CAR-T Clinical Trial Data Delivery: Accelerating Data Integrity and Analysis Timelines | Fortrea Case Study",
"description": "This Fortrea case study explores how a proactive clinical data management and site support strategy helped meet aggressive data delivery timelines in one of the first-ever CAR-T studies involving pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) and relapsed/refractory B-cell non-Hodgkin lymphoma. As part of a broader CAR-T cell therapy development program, the study required management of significant operational complexity while maintaining high standards of data integrity and data quality. Fortrea implemented a focused approach centered on prioritizing site support, overseeing critical data review activities, accelerating data analysis readiness, and proactively addressing study challenges throughout execution. By supporting data integrity efforts and streamlining operational processes, Fortrea delivered primary analysis deliverables ahead of schedule, enabling timely sponsor decision-making and successful progression of the pediatric CAR-T clinical development program.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-14",
"dateModified": "2026-04-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/car-t-pediatric-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}